Immatics N.V. Overview
Pro stress-test →Immatics N.V. is a clinical-stage biopharmaceutical company developing T cell receptor (TCR) based immunotherapies for solid tumors through two modalities: adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. The company is primarily focused on research and development of PRAME-directed immunotherapies that harness the power of T cells for cancer treatment.
Strategic Profile
Pro stress-test →Immatics is entering a pivotal period advancing toward Phase 3 SUPRAME trial interim and final analyses for its lead candidate anzu-cel while preparing for commercialization in 2027, with multiple meaningful clinical readouts across the PRAME franchise expected in 2026. The company projects cash reach into 2028 with €453.6 million in financial assets as of March 31, 2026.
Competitive Landscape
Pro stress-test →Immatics positions itself as having the broadest PRAME franchise with multiple indications and modalities across adoptive cell therapies and bispecific TCR therapeutics. Primary competitors in TCR-based immunotherapy and advanced cell therapy space include Juno Therapeutics (Celgene), Fate Therapeutics, Kite Pharma (Gilead), and emerging TCR-focused companies like Bone Biologics and Atheneum Therapeutics.
Industry Context
Immatics N.V. operates in TCR-based cell therapy for solid tumors.
Key facts
Founded: 1996 · Headquarters: Tübingen, Germany · Employees: 100-500 · Revenue: $37.3M (TTM as of Q1 2026) · Market cap: $1.3B